Zoetis Inc. (ETR:ZOE)
Germany · Delayed Price · Currency is EUR | Market Cap | 31.10B -31.9% |
| Revenue (ttm) | 8.36B +0.9% |
| Net Income | 2.21B -4.7% |
| EPS | 5.35 +0.7% |
| Shares Out | n/a |
| PE Ratio | 14.05 |
| Forward PE | 13.31 |
| Dividend | 1.83 (2.43%) |
| Ex-Dividend Date | Oct 30, 2026 |
| Volume | 317 |
| Open | 75.06 |
| Previous Close | 73.08 |
| Day's Range | 74.34 - 75.40 |
| 52-Week Range | 61.16 - 114.98 |
| Beta | 0.68 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Zoetis
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and ... [Read more]
Financial Performance
In 2025, Zoetis's revenue was $9.47 billion, an increase of 2.28% compared to the previous year's $9.26 billion. Earnings were $2.67 billion, an increase of 7.52%.
Financial numbers in USD Financial StatementsNews
Zoetis announces USDA licensed Cytopoint Plus for allergic dermatitis in dogs
Zoetis (ZTS) announced that the United States Department of Agriculture, USDA, has licensed Cytopoint Plus for the treatment of allergic dermatitis in dogs. Cytopoint Plus is the first and only…
Zoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic Dermatitis
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Cytopoint Plus is the first and only USDA-licensed next-generation mAb that provides 75 days of allergic itch relief in a single injection.
Zoetis to Participate in the Jefferies Global Healthcare Conference in London
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fires...
Zoetis price target raised to $85 from $80 at Stifel
Stifel raised the firm’s price target on Zoetis (ZTS) to $85 from $80 and keeps a Hold rating on the shares. Zoetis delivered revenue and EPS upside in Q3, but…
Zoetis plans cautiously for 2027 as pet owners cut back on vet visits, shares fall
Animal health company Zoetis said on Thursday it was planning cautiously for 2027 as rising veterinary costs and intensifying competition weigh on its companion-animal business.
Zoetis Earnings Call Transcript: Q3 2026
Q3 revenue fell 1% and adjusted net income fell 7% as companion animal softness and competition offset livestock and diagnostics growth. FY2026 guidance moved to the high end for revenue, with 2027 planning remaining cautious.
Zoetis Slides: Q3 2026
Zoetis has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Zoetis Earnings release: Q3 2026
Zoetis released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Zoetis Quarterly report: Q3 2026
Zoetis has published its Q3 2026 quarterly earnings report on November 5, 2026.
Zoetis reports Q3 adjusted EPS $1.75, consensus $1.51
Reports Q3 revenue $2.4B, consensus $2.3B.”Our third-quarter performance was in line with our expectations. Continued pressure in Companion Animal was partially offset by growth in Livestock and Diagn...
Zoetis raises FY26 adjusted EPS view $6.25-$6.35 from $6.15-$6.25
Consensus $6.26. Narrowed revenue to a range of $9.22B to $9.32B, consensus $9.29B.
Zoetis Announces Third Quarter 2026 Results; Highlights Progress Advancing Innovation Across Diversified Portfolio and Narrows Full Year 2026 Revenue Guidance, Raises Full Year 2026 Adjusted EPS Guidance
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today reported its financial results for the third quarter of 2026. "Our th...
Zoetis price target lowered to $82 from $85 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Zoetis (ZTS) to $82 from $85 and keeps an Overweight rating on the shares.
Zoetis price target raised to $85 from $80 at UBS
UBS raised the firm’s price target on Zoetis (ZTS) to $85 from $80 and keeps a Neutral rating on the shares.
Zoetis price target raised to $85 from $80 at UBS
UBS raised the firm’s price target on Zoetis (ZTS) to $85 from $80 and keeps a Neutral rating on the shares.
Zoetis announces FDA approval of Convenia RTU for Dogs
Zoetis (ZTS) announced that the U.S. FDA has approved Convenia RTU for Dogs for the treatment of susceptible bacterial skin infections in dogs. For many families, administering oral antibiotics daily…
Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Convenia RTU for Dogs provides up to 14 days of antibiotic treatment in a single dose for susceptible bacterial skin infections.
Zoetis downgraded to Hold from Buy at Jefferies
Jefferies analyst Keith Devas downgraded Zoetis (ZTS) to Hold from Buy with a price target of $83, down from $103. The firm cites the company’s softer pricing environment for the…
Zoetis initiated with a Neutral at Goldman Sachs
Goldman Sachs initiated coverage of Zoetis (ZTS) with a Neutral rating and $74 price target The firm is we constructive on the company’s long-term outlook given its “industry-leading position and…
Zoetis appoints Iris Knobloch to its board of directors
Zoetis (ZTS) announced the appointment of Iris Knobloch to its Board of Directors, effective as of December 1, 2026. Knobloch currently serves on the boards of Deezer, Lazard, and Vail…
Zoetis Appoints Iris Knobloch to its Board of Directors
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced the appointment of Iris Knobloch to its Board of Directors, effective as of December 1, 2026. With deca...
Zoetis Declares Fourth Quarter 2026 Dividend
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the fourth quarter of 2026. The dividend will ...
Zoetis put volume heavy and directionally bearish
Bearish flow noted in Zoetis (ZTS) with 2,293 puts trading, or 1.3x expected. Most active are Mar-27 50 puts and Mar-27 65 puts, with total volume in those strikes near…
Zoetis announces peer-review publication on Simparica Trio
New peer-reviewed findings published in the journal Parasites & Vectors show that Zoetis (ZTS)’ Simparica Trio protected more dogs from adult heartworm infection than NexGard Plus in a controlled, hea...
New Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Drug-resistant heartworm is a growing concern for veterinarians and pet owners as resistant heartworm populations emerge. New research shows t...